Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Post-tuberculosis lung disease: towards prevention, diagnosis, and care.
Lancet Resp. Med. 13, 460-472 (2025)
There is a growing body of data describing the high burden of respiratory sequelae seen among tuberculosis survivors, including children, adolescents, and adults. This group of sequelae are known as post-tuberculosis lung disease and include parenchymal damage, airway disease, and pulmonary vascular disease. It is thought that approximately half of pulmonary tuberculosis survivors have ongoing structural pathology, lung function impairment, or respiratory symptoms after the resolution of active disease. Post-tuberculosis lung disease has been associated with adverse patient outcomes, including persistent symptoms and functional impairment, ongoing health seeking, and impacts on income and employment. There is still much to understand about the epidemiology and nature of post-tuberculosis lung disease, but in this Review we focus on strategies for prevention, diagnosis, and care to inform the ongoing work of tuberculosis-affected communities, health-care providers, researchers, and policy makers. We summarise recent data, highlight evidence gaps, and suggest key research priorities for those working in the field.
Impact Factor
Scopus SNIP
Altmetric
32.800
0.000
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Pulmonary Tuberculosis; Tb; Health; Rehabilitation; Interventions; Chemotherapy; Prevalence; Mortality; Burden; Adults
Sprache
englisch
Veröffentlichungsjahr
2025
HGF-Berichtsjahr
2025
ISSN (print) / ISBN
2213-2600
Zeitschrift
Lancet Respiratory Medicine, The
Quellenangaben
Band: 13,
Heft: 5,
Seiten: 460-472
Verlag
Elsevier
Verlagsort
Oxford
Begutachtungsstatus
Peer reviewed
Institut(e)
Research Unit Global Health (UGH)
POF Topic(s)
30205 - Bioengineering and Digital Health
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-540001-003
Förderungen
US National Institutes of Health
UK Government
UK National Institute for Health and Care Research
UK Government
UK National Institute for Health and Care Research
WOS ID
001484426800001
Scopus ID
105002780487
PubMed ID
40127662
Erfassungsdatum
2025-05-09